# Hemophilia B

Closing the Treatment Gap: Weiguang Biological Advances Hemophilia B Candidate in China

Weiguang Biological has received regulatory approval to begin clinical trials for Human Coagulation Factor IX, targeting Hemophilia B. This development marks a significant step in China's domestic rare disease treatment capabilities, though the company warns of the long-term risks inherent in drug development.